Thailand To Allow Generic Of Taxotere Under CL Policy
This article was originally published in PharmAsia News
Executive Summary
Thailand's drug authority says it intends to use its compulsory licensing policy to import a generic of the Sanofi Aventis breast cancer drug Taxotere (docetaxel). The Government Pharmaceutical Organisation says it also will follow through on plans to use its CL policy to import two other cancer generics, for Roche/OSI Pharmaceuticals' Tarceva (erlotinib hydrochloride) and the Novartis drug Femara (letrozole). The Taxotere generic is to be supplied by India's Dabur Pharma, which is expected to deliver its first thousand doses soon, at 1 percent of the Sanofi price. (Click here for more
You may also be interested in...
Thailand’s Public Health Minister Asked To Step Down For Failing To Report Shareholdings
PERTH, Australia - Thailand's Public Health Minister Chaiya Sasomsab may have to step down from his post after failing to report his wife's shareholdings in a company, according to the Bangkok Post
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.